panobinostat   

GtoPdb Ligand ID: 7489

Synonyms: Farydak® | LBH-589 | LBH589
panobinostat is an approved drug (EMA & FDA (2015))
Compound class: Synthetic organic
Comment: Panobinostat is a non-selective histone deacetylase (HDAC) inhibitor [1-2].
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: panobinostat

2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 4
Rotatable bonds 8
Topological polar surface area 77.15
Molecular weight 349.18
XLogP 2.98
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Canonical SMILES ONC(=O)C=Cc1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2
Isomeric SMILES ONC(=O)/C=C/c1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2
InChI InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+
InChI Key FPOHNWQLNRZRFC-ZHACJKMWSA-N
No information available.
Summary of Clinical Use
Panobinostat was approved in 2015 for the treatment of multiple myeloma. Panobinostat is being assessed in clinical trials as a treatment for various other forms of cancer, including several hematologic neoplasms, prostate and breast cancers, metastatic melanoma, non-small cell lung cancer and recurrent glioblastoma and as an anti-HIV therapy (NCT01680094). Click here to link to ClinicalTrials.gov's full list of panobinostat studies.
Mechanism Of Action and Pharmacodynamic Effects
Inhibition of histone deacetylase enzymes by panobinostat is believed to cause apoptosis of malignant cells or slow the over-development of plasma cells in myeloma patients.
External links